Results 171 to 180 of about 352,265 (309)

Integrative Multi-Omics Analysis Reveals the Characteristic Metabolic Signature of Glioma and Enables Plasma-Based Liquid Biopsy. [PDF]

Research (Wash D C)
Jiang Y, Lan Y, Wang Y, Chen S, Shen Y, Chu S, Dong Y, Li L, Zhang H, Lu Z, Wang Y, Lu J, Li X, Hao F, Yue Q, Guo H.   +15 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

SP1-IKBIP axis promotes the proliferation and invasion of glioma with Wnt/β-catenin associated epithelial-mesenchymal transition. [PDF]

Am J Cancer Res
Liu N, Zhao M, Xu L, Cui Y, Tian Y, Li J, Hu X, Zhang T, Zhen H, Tu Y.   +9 more
europepmc   +1 more source

RETRACTION: Histone Lactylation‐Driven Upregulation of VRK1 Expression Promotes Stemness and Proliferation of Glioma Stem Cells

Advanced Science, EarlyView.
Abstract RETRACTION: J. Li, C. Tang, X. Zhang, R. Xing, and Q. Guo, “Histone Lactylation‐Driven Upregulation of VRK1 Expression Promotes Stemness and Proliferation of Glioma Stem Cells,” Advanced Science 12, no. 44 (2025): e03897, https://doi.org/10.1002/advs.202503897.
wiley   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression. [PDF]

Inflamm Res
Erdem S, Haliloglu Y, Uslu IN, Houran M, Ulutabanca H, Vural A, Erturhan MB, Canatan H, Eken A.   +8 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Acetylation modification in malignant progression and therapeutic resistance of gliomas. [PDF]

Front Cell Dev Biol
Zhang J, Wang M, Wang H, Jiang X, Zou H.
europepmc   +1 more source

Engineered B7‐H3 Binding in Modular Gp2 Miniproteins

Biotechnology and Bioengineering, EarlyView.
ABSTRACT B7‐H3, an important immune checkpoint modulator of T‐cell function, is a tumor vasculature biomarker and is overexpressed in a variety of cancers. Its expression is associated with tumor growth, metastasis, and poor clinical prognosis, which makes B7‐H3 an appealing target for diagnostics and therapeutics.
Abbigael Harthorn, Hannah K. Windsor, Zachary Schmitz, Nathaniel Cheung, Ebube Agwaramgbo, Benjamin J. Hackel   +5 more
wiley   +1 more source

Patterns and quality of therapeutic care for glioma: a population-based study in Belgium between 2016 and 2019. [PDF]

ESMO Open
Vanhauwaert D, Vanschoenbeek K, Silvermit G, Lombard A, Liefhooghe N, Lammens M, Dedeurwaerdere F, Whenham N, De Gendt C, Boterberg T, De Vleeschouwer S.   +10 more
europepmc   +1 more source